DR. JEROME J. SCHENTAG, is a professor of Pharmaceutical Sciences and Pharmacy at U/B. He received his B. S. degree in Pharmacy from the University of Nebraska, and his Pharm D. degree from the Philadelphia College of Pharmacy. He then completed a postdoctoral fellowship in Clinical Pharmacokinetics at the State University of New York at Buffalo, He is presently the Director of the Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System. His research interests include the effects of acute and chronic diseases on the Pharmacokinetics and Pharmacodynamics of Antibiotics and Cardiovascular Medications, and the relationships between Pharmacokinetics and Toxicity of medications used in Critically Ill Patients.
Address:
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
445 Hochstetter Hall
Buffalo NY 14260
Voicemail: 716-839-4931 x204
Cell Phone: 716-867-0550
Fax: 716-839-5138
Click here to send me email: schentag@buffalo.edu
Schentag JJ, Cerra FB, Calleri G, DeGlopper E, Rose JQ, Bernhard H. Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1:177-181, 1979.
Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 19:859-866, 1981.
Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I). Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP, Ann Pharmacother 25:1050-1057, 1991.
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents Chemother 37:1073–1081, 1993.
Rifenburg RP, Hanson SC, Tuttle JA, Paladino JA, Schentag JJ. Use of benchmarking techniques to analyze the strategies hospitals use to control antibiotic expenditures. Am J Health Syst Pharm. 53: 2054-2062, 1996.
Alioth C, Blum RA, D'Andrea DT, Kochak GM, Teng L, Ziehmer BA, Schentag JJ, Chan KKH. Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCL in volunteers. Pharm Res 10:1688–1692, 1993.
Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J, Yacobi A. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol 34:111–119, 1994.
Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve (AUIC) is more rapid for ciprofloxacin than for cefmenoxime. Annals of Pharmacother. 28:863–868, 1994.
Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zamek RL, Haverstock DC, Reinhart HH, Echols RM. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother 38:547-557, 1994.
Paladino JA, Rainstein MA, Serrianne DJ, Przylucki JE, Welage LS, Collura ML, Schentag JJ. Ampicillin/sulbactam versus cefoxitin for prophylaxis in high risk patients undergoing abdominal surgery. Pharmacotherapy 14:734–739, 1994.
Amsden GW, Goss TF, Harrison NJ, D'Andrea DT, Schentag JJ. Pharmacodynamics of bolus famotidine vs infused cimetidine, ranitidine, and famotidine. Journal of Clinical Pharmacology 34: 1191–1198, 1994.
Birmingham MC, Nix DE, Cumbo TJ, Collins DA, Wels PB, Schentag JJ. The development of a bedside algorithm capable of targeting antiendotoxins to the responder subpopulations. Therapeutic Drug Monitoring 15:503–509, 1994.
Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activity of ciprofloxacin against strains of S. pneumoniae, S. aureus and P. aeruginosa for which MICs are similar. Antimicrob Agents Chemother 38:2730–2737, 1994.
Li RCK, Nix DE, Schentag JJ. Interaction between ciprofloxacin and metal cations: Its influence on physiochemical characteristics and antibacterial activity. Pharmaceutical Research 11:917–920, 1994.
Huh KS, Wilton JH, Nix DE, Schentag JJ. Structures and biological activities of tobramycin-ticarcillin adducts. J Pharm Sci 83:763–767, 1994.
Li RCK, Nix DE, Schentag JJ. Pharmacodynamic modeling of bacterial kinetics: Beta-lactam antibiotics against Escherichia coli. J Pharm Sci 83: 970-975, 1994.
Schentag JJ. Correlation of Pharmacokinetics and Efficacy: Determine the breakpoint between success and failure. British J Intensive Care. Suppl (October): 14-16, 1994
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinetics 28(2):143–160, 1995.
Kosoglou T, Kazierad DJ, Schentag JJ, Patrick JE, Heimark L, Radwanski E, Christopher D, Flannery BE, Affrime MB. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. J Clin Pharmacol 35:151–158, 1995.
Schentag JJ. Antibiotic treatment of acute otitis media in children: dosing considerations. Pediatr Infect Dis J 14: S29–32, 1995.
Schentag JJ. Understanding and managing microbial resistance in institutional settings. Am J Health-Syst Pharm 52(Suppl 2):S9–14, 1995.
Kazierad DJ, Wojcik GJ, Nix DE, Goldfarb AL, Schentag JJ. The effect of verapamil on the nephrotoxic potential of gentamicin, as measured by urinary enzyme excretion in healthy volunteers. J Clin Pharmacol 35:196-201, 1995.
Nix DE, Schentag JJ. The role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Diagnostic Microbiol Infect Dis 22:71–76, 1995.
Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 36:385–394, 1995.
Ballow CH, Wels PB, Welage LS, Walczak P, Williams JS, Schentag JJ. A double blind, randomized comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in abdominal infections. Am J Therapeutics 2: 373–377, 1995.
Hyatt JM, Nix DE, Stratton CW, Schentag JJ. In-vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1171–1716, 1995.